Innovative Delivery Technology Pulmatrix's proprietary iSPERSE™ technology for respiratory and non-respiratory therapies offers a unique platform that can be leveraged for partnerships or licensing opportunities with companies seeking advanced inhalation delivery systems.

Expanding Clinical Pipeline With ongoing Phase 2 studies for PUR3100 and a recently launched Phase Ib trial for PUR1800, there are significant opportunities for collaborating with Pulmatrix on clinical development, trial supply, or strategic funding to advance promising therapies.

Recent Corporate Merger The merger with Cullgen Inc. expands Pulmatrix's capabilities and market reach, creating potential cross-selling opportunities or collaborative ventures in the biotech and pharmaceutical sector.

Focus on Pulmonary Disorders Pulmatrix's focus on inhaled therapies for respiratory diseases such as COPD presents opportunities to partner with healthcare providers, device manufacturers, or pharmaceutical companies targeting pulmonary health solutions.

Research & Publications Focus Published clinical results and peer-reviewed studies increase credibility and visibility, making Pulmatrix an attractive partner for research collaborations, academic-industry joint ventures, or licensing discussions with innovators in respiratory medicine.